EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters

Yuki Ujihira iD, Viktor Georgiev iD, Kayode Ogungbenro iD, Aleksandra Galetin iD

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.70023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Yuki Ujihira und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Solute Carrier Organic Anion Transporter Family Member 1B3, Organic Anion Transporters, Sodium-Independent, Models, Biological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endogenous biomarkers for drug transporters are an emerging tool for the assessment of transporter‐mediated drug–drug interactions (DDI). Glycochenodeoxycholic acid 3‐O‐sulfate (GCDCA‐S) has been proposed as a Tier 2 biomarker of hepatic OATP1B3 and renal OAT3 transporters by the International Transporter Consortium. However, there are currently no mechanistic models developed for this biomarker. This study aimed to characterize the synthesis and elimination of this biomarker through population pharmacokinetic (POP‐PK) modeling of GCDCA‐S plasma and urine data in the presence and absence of OATP1B inhibitor rifampicin and OAT3 inhibitor probenecid. Simultaneous fitting of rifampicin and probenecid interaction data incorporated the inhibitory effect of rifampicin on GCDCA‐S hepatic clearance (CL h ) and probenecid inhibitory effect on both renal (CL R ) and hepatic (CL h ) clearance parameters, assuming no effect on the synthesis of GCDCA‐S. The POP‐PK model successfully described the observed data for GCDCA‐S, with reasonable standard errors (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Solute Carrier Organic Anion Transporter Family Member 1B3Organic Anion Transporters, Sodium-IndependentModels, BiologicalHumansRifampinBiomarkersProbenecidDrug InteractionsLiver-Specific Organic Anion Transporter 1MaleAdultFemaleYoung Adult

Substanzen

Solute Carrier Organic Anion Transporter Family Member 1B3RifampinBiomarkersOrganic Anion Transporters, Sodium-IndependentProbenecidSLCO1B3 protein, humanLiver-Specific Organic Anion Transporter 1SLCO1B1 protein, humanorganic anion transport protein 3

Autor:innen und Institutionen

  • Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK.
  • Laboratory for Safety Assessment and ADME, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, Shizuoka, Japan.
  • Pharmaceutical Sciences, Roche Innovation Center Welwyn, Roche Pharma Research and Early Development, Welwyn, UK.

ORCID-Profile: Yuki Ujihira, Viktor Georgiev, Kayode Ogungbenro, Aleksandra Galetin

Zitieren

APA

Ujihira, Y., Georgiev, V., Ogungbenro, K., & Galetin, A. (2025). Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70023

Vancouver

Ujihira Y, Georgiev V, Ogungbenro K, Galetin A. Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.70023

BibTeX
@article{Ujihira2025,
  author = {Ujihira, Yuki and Georgiev, Viktor and Ogungbenro, Kayode and Galetin, Aleksandra},
  title = {Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.70023}
}
Kostenlos starten →